Celiac Disease Global Market Report 2026 to 2035

How Significant Is The Future Market Potential Of The Celiac Disease Market Based On Its Projected Size And Growth Rate?
The celiac disease market size has grown rapidly in recent years. It will grow from $0.78 billion in 2025 to $0.87 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to autoimmune disease awareness, improved diagnostics, dietary management adoption, hospital gastroenterology care, patient advocacy.

The celiac disease market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to novel drug development, gluten-free food innovation, personalized nutrition, early screening programs, microbiome research. Major trends in the forecast period include rising adoption of gluten-free diets, growth of packaged gluten-free foods, expansion of drug-based therapies, increased disease awareness and diagnosis, focus on microbiome-based treatments.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

Which Major Drivers Are Strengthening Demand In The Celiac Disease Market?
The growth of personalized medicine is expected to drive the growth of the celiac disease market going forward. Personalized medicine is an approach to healthcare that customizes medical care based on an individual’s genetic profile, environment, and lifestyle. The demand for personalized medicine is rising due to the increasing availability of genetic testing, which enables more accurate diagnoses and targeted treatments tailored to individual patient needs. The growth of personalized medicine supports celiac disease treatment by allowing precise identification of genetic markers and individual immune responses, leading to more targeted and effective management strategies for each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA authorized 16 personalized therapies in 2023 targeting rare diseases, a rise compared to the 6 approved in 2022. Therefore, the growth of personalized medicine will boost the growth of the celiac disease market.

How Is The Celiac Disease Market Divided Across Its Major Segment Categories?
The celiac disease market covered in this report is segmented –

1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments
2) By Route Of Administration: Oral, Parenteral
3) By End Users: Hospitals, Homecare, Other End-Users

Subsegments:
1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy
2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages
3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

What Trends Are Driving Change Across The Celiac Disease Market Landscape?
Major companies operating in the celiac disease market are focusing on developing advanced solutions, such as anti-interleukin-15 (IL-15) antibodies, to reduce tissue damage by limiting overactive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are specialized proteins that inhibit the function of the IL-15 cytokine, helping to control immune system activity and inflammation. For instance, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, announced that the U.S. Food and Drug Administration had granted Fast Track status for TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. It is an investigational monoclonal antibody developed for individuals with celiac disease who remain on a gluten-free diet. It functions by blocking interleukin-15 (IL-15), a molecule involved in triggering the immune response that leads to intestinal harm in celiac patients. The therapy is currently being tested in a Phase 2a clinical trial to evaluate its safety and how well it works.

Which Influential Players Dominate The Competitive Environment Of The Celiac Disease Market?
Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

Get Your In-Depth Celiac Disease Market Report Now:
https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

Which Regions Stand Out As Major Contributors To Future Demand In The Celiac Disease Market?
North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company